Publications by authors named "Lara S van der Schoot"
Background: Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologics. A substantial part of patients on tumor necrosis factor (TNF)-alfa inhibitors and ustekinumab could successfully lower their dose, after following a tightly controlled DR strategy.
View Article and Find Full Text PDFArticle Synopsis
- * Patients with low disease activity had their dosing intervals prolonged by 33%, with the option to revert to normal dosing if disease flared, and 67.2% of those monitored continued the lower dose after one year.
- * Overall, cumulative drug doses and costs decreased by 22.7% over a year, suggesting that this dose reduction approach is safe and has significant potential for everyday clinical practice.
Importance: Treating older adults with psoriasis can be challenging owing to comorbidities, concomitant medication use, and consequent safety risks. Although many studies focus on the effectiveness and safety of systemic antipsoriatic therapies in the general population, their effectiveness in older adults with psoriasis has not been systematically assessed.
Objective: To evaluate the effectiveness and safety of systemic antipsoriatic therapies in patients 65 years or older.